Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-16-2026-01_58_09-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • M&A / Deals
  • Arcera and Fosun sign MoU for neuroscience innovation
  • M&A / Deals

Arcera and Fosun sign MoU for neuroscience innovation

Pharmaceutical Business Review

The initiative aligns with China's and the United Arab Emirates' (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

pharminent April 29, 2026 (Last updated: April 29, 2026)

Pharmaceutical Business Review

The initiative aligns with China’s and the United Arab Emirates’ (UAE) broader strategic objectives to enhance healthcare and the life sciences industry.

Neuroscience

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Rocket to sell PRV for $180m to advance gene therapy pipeline
Next: Novartis’ Q1 sales miss hints at industry’s utilisation of M&A remedies

Related Stories

  • M&A / Deals

Biogen to acquire RayThera for up to $1bn

pharminent June 19, 2026
  • M&A / Deals

Heart drug biotech Kardigan raises $400m in upscaled IPO

pharminent June 18, 2026
  • M&A / Deals

Cardio biotech Kardigan binds off $400M upsized IPO

pharminent June 18, 2026

You May Have Missed

  • News

pharminent June 19, 2026
wp_daily_digest_2026-06-19
  • News

pharminent June 19, 2026
  • M&A / Deals

Biogen to acquire RayThera for up to $1bn

pharminent June 19, 2026
  • News

pharminent June 18, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.